Stay in touch
Join our mailing list to stay up to date on Invitae news including publications, product updates and new programs
For patients who undergo panel or gene testing at Invitae and are found to have a clinically actionable variant, their first-degree relatives can have up to a 50% risk of having the same variant.
Recent evidence shows that only a small percentage of relatives pursue follow-up testing, in part due to cost.1,2 Reasons relatives do not pursue testing include lack of knowledge about the potential disease risk, family communication barriers, lack of access to genetics services, and cost of testing.3,4 As part of our commitment to lowering barriers to genetic testing, we now offer testing for first-degree relatives at no additional charge.
If your patient does not meet these criteria, Invitae still offers testing at a reduced price, which may be covered by insurance. Visit www.invitae.com/billing to learn more.
If you prefer to place your order on paper, you can download the Family Variant Testing/VUS Resolution requisition form (TRF920).
For family members who do not meet the criteria above, follow the steps above without including an RQ number. The information on family relationship to the original proband is required and a pedigree is still recommended.
Have questions? Log in to your account and click on the “Messages” tab to contact us about family variant testing and upload the patient's information in a secure, HIPAA-compliant manner.
1. Christiaans I et al. Update of genetic counseling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum Genet. 2008;16(10):1201-7.
2. Sharaf RN et al. Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013;11(9):1093-100.
3. Kasparian NA et al. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med. 2009;11(4):265-78.
4. Sturm AC. Cardiovascular cascade genetic testing: exploring the role of direct contact and technology. Front Cardiovasc Med. 2016;3(11).